Laquinimod

別名：ABR-215062, LAQ

製品コード：S2787 純度：99.96%

Laquinimod (ABR-215062, LAQ) is a potent immunomodulator. Phase 3.

CAS No. 248281-84-7

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 66700	国内在庫あり
5mg	JPY 46800	国内在庫あり
10mg	JPY 80000	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（2）

製品安全説明書

現在のバッチを見る： S278701 DMSO] 61 mg/mL] false] Ethanol] 1 mg/mL] false] Water] Insoluble] false 純度： 99.96%

99.96

Laquinimod関連製品

関連製品	Cl-amidine TAPI-1 Bindarit Sulfasalazine Ipilimumab (anti-CTLA-4) Pimecrolimus Tempol Amlexanox Anti-mouse CD8α-InVivo Tranilast Sinomenine Rituximab (anti-CD20) N-Acetylcysteine amide Geniposidic acid GI254023X Phenylbutazone Hydrocortisone acetate CORM-3 Bestatin (Ubenimex) ATP Acacetin Germacrone Oxymatrine Imiquimod Gastrodin Atractylenolide I Y-320 Amodiaquine hydrochloride Sinomenine hydrochloride Tomatidine Hydrochloride Thymoquinone Demethylzeylasteral (T-96) Lupeol Flufenamic acid Quercitrin Iguratimod Calycosin Sanguinarine Punicalagin Z-Guggulsterone Fenamic acid Tiragolumab (anti-TIGIT) Geniposide Diclofenac Epolamine Thymol Lodoxamide Tromethamine Jujuboside A PMX-53 6-Shogaol Isoliensinine Tiaprofenic acid Diclofenac Potassium Arachidonic acid Astragalin Linarin Isoliquiritin Coumarin Platycodin D Pipecolic acid Umbelliferone Thymopentin Salvianolic acid A VGX-1027 Sinigrin Fenoprofen calcium hydrate Isovitexin Buddlejasaponin IVb Fenoprofen Calcium Lysionotin Liensinine Ginsenoside CK Lentinan Wogonoside Bakuchiol Carnosol Madecassic acid Acetylharpagide Anwuligan Ginkgetin Eicosapentaenoic Acid (EPA) Avacopan Tryptanthrin Pranlukast Cortisone	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ	もっと見る

Immunology & Inflammation related阻害剤の選択性比較

生物活性

製品説明	Laquinimod (ABR-215062, LAQ) is a potent immunomodulator. Phase 3.

In Vitro
In vitro	Laquinimod treatment at 0.1-1 μM does not affect the viability of peripheral blood mononuclear cells (PBMC). By performing the large-scale gene expression microarray analysis in PBMC from healthy subjects or relapsing-remitting multiple sclerosis (RRMS) patients, Laquinimod is shown to induce suppression of genes related to antigen presentation and corresponding inflammatory pathways. Laquinimod induces activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells. Laquinimod displays significant effects on immune modulation related to the suppression of antigen presenting mechanism followed by a decrease of chemotaxis and adhesion, and exhibits potent anti-inflammatory potency through the suppression of the NF-κB pathway that concordantly leads to the activation of apoptosis of immuno-competent cells. ^[5]
細胞実験	細胞株	PBMC
	濃度	Dissolved in PBS, final concentrations ~1 μM
	反応時間	24 hours
	実験の流れ	The peripheral blood mononuclear cells (PBMC) are incubated with Laquinimod for 24 hours. Cell viability is measured on total PBMC by propidium iodide (PI) staining using an automated cell counter. Protein expression level is assessed in PBMC samples by Western blot using anti-HLA-DQA/DQB monoclonal antibodies.

In Vivo
In Vivo	Administration of Laquinimod (0.16-16 mg/kg/day) dose-dependently inhibits the incidence of experimental autoimmune neuritis (EAN) in Lewis rats, ameliorates clinical signs and inhibits P0 peptide 180-199-specific T cell responses as well as the inflammation and demyelination in the peripheral nerves, suggesting that Laquinimod may mediate its effects by regulation of Th1/Th2 cytokine balance. ^[1] Laquinimod significantly inhibits the development of murine acute experimental autoimmune encephalomyelitis (EAE), being approximately 20 times more potent than the immunomodulator roquinimex. ^[2] Laquinimod treatment inhibits the development of experimental autoimmune encephalomyelitis (EAE) in the Lewis rat in a dose-dependent manner, and shows better disease inhibitory effects as compared to roquinimex (Linomide). ^[3] Laquinimod potently inhibits the development of chronic experimental autoimmune encephalomyelitis (chEAE) in IFN-beta k.o. mice and wild type mice. ^[4] Laquinimod reduces clinical signs, inflammation, and demyelination in C57BL/6 mice with active EAE induced with MOG(35-55) peptide, and down-regulates VLA-4-mediated adhesiveness and pro-inflammatory cytokines such as IL-17. ^[6] The study of Laquinimod in the mice model of EAE using a conditional BDNF knockout strain lacking BDNF expression in myeloid cells and T cells (LLF mice) indicates Laquinimod also modulates autoimmune demyelination via induction of brain-derived neurotrophic factor (BDNF). ^[7]
動物実験	動物モデル	Lewis rats with experimental autoimmune neuritis (EAN) induced by inoculation with peripheral nerve myelin P0 protein peptide 180-199 and Freund's complete adjuvant
	投与量	0.16, 1.6 and 16 mg/kg/day
	投与経路	Administered via a daily subcutaneous injection

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT06161415	Not yet recruiting	Uveitis	Quan Dong Nguyen\|Global Ophthalmic Research Center (GORC)\|Stanford University	January 2024	Phase 1
NCT05187403	Completed	Eye Diseases	Active Biotech AB	December 9 2021	Phase 1
NCT02772523	Completed	Alzheimer''s Disease	Barcelonabeta Brain Research Center Pasqual Maragall Foundation	May 2016	Not Applicable
NCT02085863	Completed	Pharmacokinetics\|Pharmacodynamics	Teva Branded Pharmaceutical Products R&D Inc.	February 2014	Phase 1
NCT01975298	Withdrawn	Relapsing Remitting Multiple Sclerosis	Teva Branded Pharmaceutical Products R&D Inc.	January 2014	Phase 3

参考
[1] Zou LP, et al. Neuropharmacology, 2002, 42(5), 731-739. [2] Brunmark C, et al. J Neuroimmunol, 2002, 130(1-2), 163-172. [3] Yang JS, et al. J Neuroimmunol, 2004, 156(1-2), 3-9. [4] Runstr?m A, et al. J Neuroimmunol, 2006, 173(1-2), 69-78. [5] Gurevich M, et al. J Neuroimmunol, 2010, 221(1-2), 87-94. [6] Wegner C, et al. J Neuroimmunol, 2010, 227(1-2), 133-143. + 展開

参考

+ 展開

化学情報

分子量	356.8	化学式	C₁₉H₁₇ClN₂O₃
CAS No.	248281-84-7	SDF	Download Laquinimod SDFをダウンロードする
Smiles	CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 61 mg/mL ( (170.96 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 1 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):